<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05627401</url>
  </required_header>
  <id_info>
    <org_study_id>SYSKY-2022-349-01</org_study_id>
    <nct_id>NCT05627401</nct_id>
  </id_info>
  <brief_title>Customized Multiple Orbital Wall Decompression for Sight-threatening Graves's Ophthalmopathy</brief_title>
  <official_title>Customized Modified Multiple Orbital Wall Decompression With Fat Removal for Sight-threatening Graves's Ophthalmopathy : a Retrospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Graves' orbitopathy (GO) is an disfiguring and disabling autoimmune condition.&#xD;
      Sight-threatening GO is an most severe form and occurs in about 5% of patients with Graves'&#xD;
      disease. It can cause blurred vision, color vision and vision function damage, and affects&#xD;
      the quality of life. The goal of this retrospective cohort study is to propose a customized&#xD;
      orbital decompression algorithm for patients with sight-threatening Graves'ophthalmopathy and&#xD;
      to explore the therapeutic effect of customized orbital decompression in sight-threatening&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>BCVA</measure>
    <time_frame>12 months</time_frame>
    <description>best corrected visual acuity in logMAR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CAS</measure>
    <time_frame>12 months</time_frame>
    <description>clinical activity score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>proptosis</measure>
    <time_frame>12 months</time_frame>
    <description>proptosis in mm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EVP</measure>
    <time_frame>12 months</time_frame>
    <description>Visual Evoked Potential</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GO-QOL</measure>
    <time_frame>12 months</time_frame>
    <description>Graves' Ophthalmopathy Quality of Life</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Thyroid Eye Disease</condition>
  <arm_group>
    <arm_group_label>Single Group Assignment</arm_group_label>
    <description>patients with sight-threatening Graves orbitopathy (GO) who underwent customized/individual multiple orbital wall decompression plus fat removal</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Modified multiple orbital wall decompression</intervention_name>
    <description>Thyroid dysfunction of all patients is stabilized by ATDs until treatment of TAO is completed. All patients with sight-threatening GO were admitted for emergency steroid pulse therapy. And additional drugs for protecting gastrointestinal mucous membrane, potassium and calcium supplements, and sedatives were used. All emergency cases, whose signs of visual impairment clinically attributable to GO existed despite first-line steroid treatment, were referred and discussed at the surgical board of our interdisciplinary center for prompt surgical orbital decompression. Urgent orbital decompression was performed when response is absent or poor within 1-2 weeks.</description>
    <arm_group_label>Single Group Assignment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This was a retrospective cohort study of patients with sight-threatening Graves orbitopathy&#xD;
        (GO) who underwent customized/individual multiple orbital wall decompression plus fat&#xD;
        removal at Sun Yat-Sen Memorial Hospital from Jan. 2017 to Dec. 2021.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sight-threatening patients undergoing interdisciplinary discussion and orbital&#xD;
             decompression operation.&#xD;
&#xD;
          -  The sight-threatening GO refer to those with DON, exposure keratitis or corneal&#xD;
             breakdown.&#xD;
&#xD;
          -  DON was diagnosed according to the following clinical findings including optic nerve&#xD;
             head edema, visual field defect, impaired color vision, afferent pupil defect, retinal&#xD;
             folds, radiologic evidence of apical optic nerve compression or globe subluxation.&#xD;
&#xD;
          -  Diagnosis of exposure keratitis or corneal breakdown was made based on physical exam&#xD;
             signs, e.g. microepithelial defects, abrasion or ulcer. A minimum follow-up of 12&#xD;
             months was required for inclusion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients were excluded if exophthalmos, rather than acute visual loss, was the&#xD;
             indication for surgery.&#xD;
&#xD;
          -  Cases with a history of previous ocular surgery, glaucoma, and visual defects from&#xD;
             other ocular conditions were excluded from the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Peng Tian, PhD., M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peng Tian, PhD., M.D.</last_name>
    <phone>+8615913171205</phone>
    <email>tianpeng3@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mei Wang, PhD., M.D.</last_name>
    <phone>+8613724856155</phone>
    <email>wangmei2@mail.sysu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen Memorial Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peng Tian, PhD., M.D.</last_name>
      <phone>+86 81332449</phone>
      <email>tianpeng3@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 17, 2022</study_first_submitted>
  <study_first_submitted_qc>November 17, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2022</study_first_posted>
  <last_update_submitted>November 17, 2022</last_update_submitted>
  <last_update_submitted_qc>November 17, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Orbital decompression</keyword>
  <keyword>Graves' orbitopathy</keyword>
  <keyword>Dysthyroid optic neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Graves Ophthalmopathy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Medical records or outpatient examination records cannot be shared by hospitals across the country.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

